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To evaluate whether parameters of obstructive sleep apnoea (OSA) associate with cholesterol metabolism before and after weight
reduction, 42 middle-aged overweight subjects with mild OSA were randomised to intensive lifestyle intervention (𝑁 = 23) or to
control group (𝑁 = 18) with routine lifestyle counselling only. Cholesterol metabolism was evaluated with serum noncholesterol
sterol ratios to cholesterol, surrogate markers of cholesterol absorption (cholestanol and plant sterols) and synthesis (cholestenol,
desmosterol, and lathosterol) at baseline and after 1-year intervention. At baseline, arterial oxygen saturation (SaO2 ) was associated
with serum campesterol (𝑃 < 0.05) and inversely with desmosterol ratios (𝑃 < 0.001) independently of gender, BMI, and
homeostasis model assessment index of insulin resistance (HOMA-IR). Apnoea-hypopnoea index (AHI) was not associated with
cholesterol metabolism. Weight reduction significantly increased SaO2 and serum cholestanol and decreased AHI and serum
cholestenol ratios. In the groups combined, the changes in AHI were inversely associated with changes of cholestanol and positively
with cholestenol ratios independent of gender and the changes of BMI andHOMA-IR (𝑃 < 0.05). In conclusion, mild OSA seemed
to be associated with cholesterol metabolism independent of BMI and HOMA-IR. Weight reduction increased the markers of
cholesterol absorption and decreased those of cholesterol synthesis in the overweight subjects with mild OSA.
1. Introduction
Obstructive sleep apnoea (OSA) characterized by repeated
episodes of apnoea and hypopnoea during sleep is one of
the most common sleep disturbances [1]. OSA is indepen-
dently associated with hypertension, cardiovascular diseases,
metabolic syndrome, insulin resistance, and type 2 diabetes
[2–7]. Furthermore, recent epidemiological studies have
concluded that OSA is an important risk factor for mortality,
particularly due to coronary artery disease [8, 9]. However,
the underlying mechanisms explaining these associations
are rather complex, and although several possibilities have
been proposed, they are not entirely accepted. In general,
atherogenesis as well as OSA is considered as slow processes,
and the onset is likely to begin years before any symptoms
appear. We have earlier demonstrated that even mild OSA is
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associated with the activation of the proinflammatory system
[10]. Furthermore, since elevated LDL cholesterol level is
one of the most important risk factors for cardiovascular
diseases, the question raises whether OSA has a role in
hypercholesterolaemia or in cholesterolmetabolism. In some,
but not in all studies, OSA has independently associated with
increased concentrations of total cholesterol and triglycerides
and decreased concentrations ofHDL cholesterol [11–14].The
mechanisms of dyslipidaemia in OSA besides obesity are not
clearly understood especially for elevated LDL cholesterol
level [15], but most likely chronic intermittent hypoxemia
(IH), a major component of OSA, may be the primary
trigger for a cascade of pathogenetic mechanisms leading
to increased triglyceride-rich lipoproteins and reduced HDL
cholesterol levels [15]. Regarding cholesterol metabolism
there are no clinical studies examining the association
between OSA and cholesterol metabolism (i.e., cholesterol
synthesis and absorption).
Themost important risk factor forOSA is obesity [16]. On
the other side, obesity interferes with cholesterol metabolism,
so that cholesterol synthesis is upregulated, and cholesterol
absorption efficiency is low [17, 18]. Accordingly, it could be
assumed that cholesterol metabolism might be disturbed in
OSA, but whether it is obesity or OSA that interferes with
cholesterol metabolism remains to be evaluated. However,
this does not change the fact that 60–90% of all patients with
OSA are obese [19] and need to be treated not only for OSA
but also other obesity related comorbidities.
It was recently demonstrated that lifestyle intervention
with weight reduction reduced both hypopnoea and espe-
cially apnoea indices and also other obesity related risk
factors for cardiovascular diseases in a vast majority of
patients with mild OSA, highlighting the importance of
an early lifestyle intervention [20]. Similarly, weight reduc-
tion decreases cholesterol synthesis and increases choles-
terol absorption in type 2 diabetics [21, 22]. It would be
interesting to know whether in subjects with OSA weight
reduction alters also cholesterol metabolism, and whether
the reduction in apnoea and hypopnoea indices are related
to cholesterol metabolism beyond obesity. Therefore, in the
present randomised interventional study two main param-
eters of OSA, that is, apnoea-hypopnoea index (AHI) and
arterial oxygen saturation (SaO
2
), were related to those of
cholesterol synthesis and absorption at baseline and after one-
year weight reduction program in middle-aged overweight
subjects with mild OSA. Cholesterol metabolism was evalu-
ated with serum noncholesterol sterols, surrogate markers of
cholesterol absorption and synthesis [23].
2. Methods
This study is a substudy of our randomised study originally
conducted to determine the effects of changes in lifestyle
with weight reduction program designed to prevent the
progression of the disease or even cure it in themost prevalent
subgroup of OSA, that is, overweight patients withmildOSA.
The detailed design of the study was previously reported [20].
2.1. Subjects. The subjects were consecutively recruited from
among patients referred to the outpatient clinics of Otorhino-
laryngology and Respiratory Medicine of Kuopio University
Hospital, Finland, because of a suspicion of OSA. The main
study population consisted of 72 subjects who completed the
1-year follow-up [20]. The inclusion criteria were age 18–65
years, overweight (BMI ≥ 28 kg/m2), and mild OSA (AHI
5–15 events/h). The exclusion criteria were active treatment
of OSA of any kind, pregnancy, chronic kidney, thyroid, or
liver disease. To the present study, an additional inclusion
criterion was the availability of both baseline and follow-up
measurements, and an additional exclusion criterion was the
presence of lipid-lowering medication.
This study was conducted according to the guidelines
laid down in the Declaration of Helsinki, and all procedures
involving human subjects were approved by the Research
Ethics Committee of the Hospital District of Northern Savo
(Kuopio, Finland). All subjects gave their written informed
consent for the study.
2.2. Intervention. A detailed description of the intervention
procedure was previously reported by Tuomilehto et al. [20].
The subjects with mild OSA were randomised to two groups.
The subjects in the intervention group were provided with a
group-based very low calorie diet (VLCD) of 600–800 kcal/d
for 12 weeks, after which they were advised regarding diet
and exercise. The lifestyle intervention lasted for 1 year and
consisted of 14 visits with the study nutritionist. The subjects
in the control group were given standard care consisting
of general oral and written information about diet and
exercise at baseline and 3-month visits by the study nurse and
physician without any specific individualised advice.
2.3. Measurements. Nocturnal cardiorespiratory monitoring
by Embletta (Embla, Broomfield, CO, USA) at home was
conducted in accordance with accepted guidelines for diag-
nosing OSA [24]. Apnoea was defined as a cessation (>90%)
of airflow for >10 s with oxygen desaturation for ≥4%.
Hypopnoea was defined as a reduction (>30%) of airflow for
>10 s with oxygen desaturation for ≥4%. AHI was defined
as the number of apnoeas and hypopnoeas per hour, and
mild OSA was defined as an AHI of 5–15 events/h [24].
Furthermore, mean arterial oxygen saturation (SaO
2
) and
time and percentage with arterial oxygen saturation <90%
were assessed. The recordings were manually evaluated by
two blinded, trained physicians.
Body weight was measured with a digital scale and height
using a stadiometer. A trained nurse measured also waist
circumference both at the baseline and at the 1-year visit.
Blood samples for biochemical assays were collected
from fasting subjects (≥12 h). Serum total and HDL choles-
terol, serum triglycerides and plasma glucose were anal-
ysed by using automated analyzer system (Konelab 60
Analyzer, ThermoFisher Scientific, Waltham, MA, USA).
LDL cholesterol was calculated according to Friedewald
equation. Plasma glucose was analysed by using automated
analyzer system (Konelab 60 Analyzer, ThermoFisher Scien-
tific, Waltham, MA, USA). Serum insulin was measured by
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using a fluoroimmunoassay system (Wallac, Perkin-Elmer,
Waltham, MA, USA). The homeostasis model assessment
index of insulin resistance (HOMA-IR) was calculated as
fasting serum insulin concentration × fasting plasma glucose
concentration/22.5 [25].
Serum cholesterol, cholesterol precursors reflecting cho-
lesterol synthesis (squalene, cholestenol, lathosterol, and des-
mosterol), plant sterols (sitosterol and campesterol), and
cholestanol reflecting cholesterol absorption [23] were quan-
tified from nonsaponifiable serum material by GLC (Agilent
7890GC System, Agilent Technologies, Wilmington, DE,
USA) equippedwith a 50m longUltra 1 capillary column (5%
Phenyl-methyl siloxane) (Agilent Technologies,Wilmington,
DE, USA) [26]. Serum values were expressed in terms of
102xmmol/mol of cholesterol (called ratio in the text) by
dividing the noncholesterol sterol concentrations with the
cholesterol value of the same GLC run to eliminate the
changing concentrations of lipoproteins (mainly LDL) that
transports noncholesterol sterols. Ratios of relative synthesis
markers/absorption markers were also calculated reflecting
cholesterol metabolism.
2.4. Statistical Analyses. Statistical analyses were performed
with SPSS for Windows 14.0 statistics program (SPSS,
Chicago, IL, USA).
Normality and homogeneity of variance assumptions
were checked before further analyses. Student’s t-test was
used to compare the baseline values and the changes between
the groups. ANOVA for repeated measurements was used to
analyse the interaction of time and group and changes over
time in between-group comparisons followed by post hoc
comparisons with Bonferroni corrections. In between-group
comparisons, gender and BMI, were included as ANCOVA.
For some variables of interest Pearson or Spearman corre-
lation coefficients were calculated. In addition, to evaluate
the effects of gender, BMI and HOMA-IR on associations of
parameters of OSA and cholesterol metabolism, a multiple
linear regression analysis was used. Variables not normally
distributed even after logarithmic transformation, nonho-
mogenous in variance, or noncontinuous were tested with
Mann-WhitneyU test or Fisher exact test. A 𝑃 value of <0.05
was considered statistically significant. The results are given
as means ± SEM.
3. Results
3.1. Baseline. A total of 41 subjects (33 men and 8 women)
fulfilled the criteria and were included into the statistical
analyses. Their mean age was 48.9 ± 1.3 years and BMI
32.5 ± 0.4 kg/m2. Thirteen subjects had antihypertensive
medication, two had thyroxin therapy, and one had oral
diabetes medication. Baseline characteristics of the subjects
in the control (𝑁 = 18) and intervention (𝑁 = 23)
groups are shown in Table 1. Despite randomisation, the
subjects in the intervention group were heavier, and their
BMI was higher and waist circumference larger than in the
control group. In addition, serum insulin concentration and
cholestenol : cholesterol ratio were greater, and HOMA-IR
tended to be significantly greater (𝑃 = 0.055) compared with
controls (Table 2). No other significant differences between
the groups were observed.
3.1.1. Baseline Associations. In the whole population, choles-
terol synthesis markers were interrelated (e.g., cholestenol
versus lathosterol 𝑟 = 0.572, 𝑃 < 0.001) as well as the absorp-
tion markers (campesterol versus cholestanol 𝑟 = 0.664,
𝑃 < 0.001). Cholesterol synthesis markers were inversely as-
sociated with the absorption markers (e.g., desmosterol
versus cholestanol 𝑟 = −0.637, 𝑃 < 0.001) suggesting that
cholesterol homeostasis was intact.
The markers of cholesterol synthesis were positively (e.g.,
desmosterol ratio 𝑟 = 0.364, 𝑃 = 0.020) and those of
cholesterol absorption inversely (e.g., cholestanol ratio 𝑟 =
−0.376, 𝑃 = 0.020) associated with BMI. The cholesterol
synthesis markers were inversely associated with serum
HDL cholesterol concentration (e.g., desmosterol ratio 𝑟 =
−0.502, 𝑃 = 0.001) and positively with serum triglycerides
(e.g., desmosterol ratio 𝑟 = 0.546, 𝑃 < 0.001), whereas
the associations between the absorption markers and HDL
cholesterol (e.g., cholestanol ratio 𝑟 = 0.316, 𝑃 = 0.040) and
triglycerides (e.g., cholestanol ratio 𝑟 = −0.343, 𝑃 = 0.028)
were opposite. No associations of the cholesterol synthesis
and absorption markers with total and LDL cholesterol were
found.
Mean total AHI was not associated with mean arterial
oxygen saturation (SaO
2
) or with any other variables, even
though AHI tended to be associated with serum cholestenol
ratio to cholesterol (𝑟 = 0.292, 𝑃 = 0.064).
SaO
2
was inversely associated with body weight (𝑟 =
−0.656, 𝑃 < 0.001) and waist circumference (𝑟 = −0.481, 𝑃 =
0.003) and positively with HDL cholesterol concentration
(𝑟 = 0.410, 𝑃 = 0.010). SaO
2
was inversely associated
with desmosterol (𝑟 = −0.595, 𝑃 < 0.001) and posi-
tively with campesterol ratios to cholesterol (𝑟 = 0.381,
𝑃 = 0.020). In multiple linear regression analysis after
adjustment with gender, BMI and HOMA-IR, the associa-
tions between SaO
2
and desmosterol and campesterol ratios
to cholesterol and desmosterol : campesterol ratio remained
significant (Table 3).
3.2. Intervention
3.2.1. Anthropometric Measurements. BMI and waist circum-
ference reduced significantly more in the intervention group
compared with the control group (−13.6% versus −2.2% and
−10.9% versus −2.2%, resp.) (Table 1) during the follow-up.
3.2.2. Serum Cholesterol, Plasma Glucose, and Serum Insulin.
Plasma glucose was similarly reduced in both study groups
(𝑃 < 0.05), but the reduction was not significant after
adjustment with gender and BMI (Table 1). The reduction in
serum insulin concentration was greater in the intervention
group compared with the controls (−43.6% versus −17.8%,
𝑃 < 0.05), but the intervention values did not differ between
the groups (Table 1). Similarly, the percentage reduction in
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Table 1: Changes in anthropometricmeasurements, plasma glucose and serum insulin concentrations, and cardiorespiratory variables during
the intervention.
Control group Intervention group
𝑃
a
𝑃
b
Baseline 12 months Baseline 12 months
Gender (M/F) 14/4 19/4 0.500
Age (y) 48.2 ± 2 49.4 ± 1.7 0.667
Weight (kg) 93.9 ± 2.9 92.2 ± 3.4 103.5 ± 2.2c 91.5 ± 2.4d,e <0.001 <0.001
BMI (kg/m2) 31.4 ± 0.6 30.9 ± 0.9 33.4 ± 0.6c 29.5 ± 0.6d,e <0.001 <0.001
Waist circumference (cm) 104.6 ± 2.3 102.9 ± 2.6 112.9 ± 2.1c 101.0 ± 2.0d,e <0.001 <0.001
P-Glucose (mmol/L)(f) 6.19 ± 0.51 5.57 ± 0.16 5.92 ± 0.19 5.59 ± 0.13 0.528 0.306
S-Insulin (mU/L) 10.18 ± 1.06 8.25 ± 1.05 14.61 ± 1.69c 7.16 ± 0.63 0.082 0.105
HOMA-IR 2.66 ± 0.33 2.08 ± 0.28 3.98 ± 0.54 1.80 ± 0.18 0.087 0.103
Total cholesterol (mmol/L) 5.17 ± 0.25 5.21 ± 0.23 4.83 ± 0.11 4.63 ± 0.16 0.246 0.369
LDL cholesterol (mmol/L) 3.13 ± 0.17 3.28 ± 0.17 3.06 ± 0.10 2.88 ± 0.14 0.116 0.226
HDL cholesterol (mmol/L) 1.13 ± 0.10 1.12 ± 0.07 0.98 ± 0.05 1.15 ± 0.06d 0.028 0.044
Total triglycerides (mmol/L)(f) 1.78 ± 0.24 1.60 ± 0.30 1.73 ± 0.17 1.32 ± 0.12 0.683 0.510
AHI (total) 9.5 ± 0.8 11.2 ± 2.0 9.8 ± 0.6 5.2 ± 1.2d,(e) 0.007 0.040
Mean SaO2 94.5 ± 0.3 93.9 ± 0.3
d 94.0 ± 0.3 94.8 ± 0.3d,e <0.001 0.001
Time with SaO2 < 90% 3.5 ± 0.9 9.2 ± 3.5 6.4 ± 2.2 4.7 ± 2.1
d,e 0.007 0.004
Percentage time with SaO2 < 90% 0.9 ± 0.2 2.3 ± 0.9
d 1.6 ± 0.5 0.8 ± 0.3d,e 0.003 0.002
Values shown are means ± SEM.
aGroup by time interaction analysed with analysis of variance for repeated measurements (GLM). If the baseline differed between groups (𝑃 < 0.06), it was
taken into account as covariance. (Gender Fisher’s exact test and age Student’s 𝑡-test).
bGroup by time interaction (gender and BMI as covariance).
c
𝑃 < 0.05 denotes a significant difference at the baseline between the groups.
d
𝑃 < 0.05 denotes a significant difference from the baseline within the groups.
e
𝑃 < 0.05 denotes a significant difference at the 12 months between the groups, (e)𝑃 > 0.05 (gender and BMI as covariance).
f
𝑃 < 0.05 denotes a significant change over time, (f)𝑃 > 0.05 (gender and BMI as covariance).
HOMA-IR was greater in the intervention group compared
with the controls (−46.7% versus −19.5%, 𝑃 < 0.05).
3.2.3. Serum Lipids. Serum total and LDL cholesterol con-
centrations were not changed during the intervention
(Table 1). Serum HDL cholesterol concentration significantly
increased in the intervention group, and the percentage
increase was greater than in the control group. However,
the intervention values did not differ between the groups
(Table 1). Serum triglyceride concentration was similarly
reduced in both study groups (𝑃 < 0.05), but the reductions
were not significant after adjustment with gender and BMI
(Table 1).
3.2.4. Cardiorespiratory Recordings. The mean total AHI at
12 months and the mean percentage change (−49.1% versus
+30.9%) during the follow-up significantly differed between
the groups (Table 1). However, after adjustment with gender
and BMI the mean total AHI only tended to be lower in the
intervention group compared with controls (𝑃 = 0.052). A
significant improvement was detected in mean SaO
2
in the
intervention group compared with the control group at 12
months (Table 1). In addition, the subjects in the intervention
group spent less time with SaO
2
< 90% during their sleep
compared with subjects in the control group (Table 1).
3.2.5. Cholesterol Synthesis and Absorption Markers. Of the
cholesterol synthesis markers, serum cholestenol ratio to
cholesterol was significantly reduced by −18.1% in the inter-
vention group, and the change was significantly different
compared with the controls (Table 2). Serum desmosterol
and lathosterol ratios to cholesterol similarly reduced in both
groups (𝑃 < 0.05), but the reductions were not significant
after adjustment with gender and BMI (Table 2). No changes
in serum squalene were found (Table 2).
Of the cholesterol absorption markers, serum choles-
tanol : cholesterol ratio significantly increased by 11.4% dur-
ing the follow-up in the intervention group, and the
change was significantly different compared with the controls
(Table 2). However, the intervention values did not differ
between the groups (Table 2). Serum campesterol and sitos-
terol ratios to cholesterol did not change (Table 2).
The changes in the concentrations of serum cholesterol
synthesis and absorption markers were in line with the
respective changes in the ratio to cholesterol (data not
shown).
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Table 2: Changes in serum noncholesterol sterols and squalene during the intervention.
Control group Intervention group
𝑃
a
𝑃
b
Baseline 12 months Baseline 12 months
Cholesterol (mg/dL) 195.9 ± 9.6 193.9 ± 9.3 181.9 ± 5.2 172.5 ± 5.6 0.219 0.413
Cholesterol synthesis markers
Squalene : cholesterol 26.5 ± 2.6 24.7 ± 2.7 23.5 ± 1.2 22.1 ± 1.7 0.860 0.408
Cholestenol : cholesterol 15.2 ± 1.4 16.9 ± 1.9 22.3 ± 2.9c 18.0 ± 2.9d,e 0.025 0.020
Desmosterol : cholesterol(f ) 66.3 ± 4.5 63.4 ± 5.2 77.8 ± 5.0 65.6 ± 2.8 0.131 0.161
Lathosterol : cholesterol(f ) 179.4 ± 14 175.1 ± 12.7 208.3 ± 13.0 178.9 ± 14.1 0.126 0.069
Cholesterol absorption markers
Campesterol : cholesterol 206.1 ± 27.7 208.2 ± 18.3 227.1 ± 24.2 235.1 ± 30.6 0.656 0.670
Sitosterol : cholesterol 108.1 ± 11.6 107.5 ± 7.7 132.5 ± 16.0 136.6 ± 16.1 0.843 0.842
Cholestanol : cholesterol 131.1 ± 5.8 130.6 ± 6.1 121.0 ± 4.6 135.5 ± 6.7d 0.002 0.004
Cholesterol metabolism markers
Squalene : Cholestanol 0.21 ± 0.03 0.20 ± 0.03 0.20 ± 0.01 0.18 ± 0.02 0.293 0.109
Cholestenol : Cholestanol 0.12 ± 0.01 0.14 ± 0.02 0.20 ± 0.03c 0.14 ± 0.02d,e 0.006 0.006
Desmosterol : Cholestanol 0.54 ± 0.06 0.52 ± 0.06 0.68 ± 0.06 0.52 ± 0.04d 0.016 0.029
Lathosterol : Cholestanol 1.42 ± 0.12 1.42 ± 0.13 1.81 ± 0.15 1.45 ± 0.17d 0.026 0.017
Values shown are means ± SEM.
aGroup by time interaction analysed with analysis of variance for repeated measurements (GLM). If the baseline differed between groups (𝑃 < 0.05), it was
taken into account as covariance.
bGroup by time interaction (gender and BMI as covariance).
c
𝑃 < 0.05 denotes a significant difference at the baseline between the groups.
d
𝑃 < 0.05 denotes a significant difference from the baseline within the groups.
e
𝑃 < 0.05 denotes a significant difference at the 12 months between the groups.
f
𝑃 < 0.05 denotes a significant change over time (f )𝑃 > 0.05 (gender and BMI as covariance).
Table 3: Associations between serum desmosterol and campesterol ratios to cholesterol and desmosterol : campesterol ratio and SaO2
∗.
Desmosterol : cholesterol Campesterol : cholesterol Desmosterol : campesterol
Beta 𝑃 value Beta 𝑃 value Beta 𝑃 value
Gender −0.264 0.062 −0.348 0.094 0.131 0.742
BMI (kg/m2) 0.047 0.732 −0.033 0.873 0.045 0.802
HOMA-IR 0.524 <0.001 −0.011 0.956 0.247 0.153
SaO2 −0.322 0.031 0.604 0.008 −0.584 0.004
𝑅
2 0.623 0.175 0.360
∗Multiple linear regression analysis models (adjustment with gender, BMI, and HOMA-IR).
Serum cholestenol, desmosterol, and lathosterol ratios to
cholestanol significantly reduced by −19.6–−25.4% during
the follow-up in the intervention group, and the changes
significantly differed from controls, but only the intervention
values of cholestenol : cholestanol ratio significantly differed
compared with controls (Table 2).
3.2.6. Associations during Intervention (Intervention + Control
Groups Combined). Figure 1 shows the percentage changes
in AHI, SaO
2
, cholestenol, and cholestanol : cholesterol ratios
in relation to weight reduction. The greater the weight
reduction, the greater the reductions in AHI and serum
cholestenol : cholesterol ratio and the increases in SaO
2
and
serum cholestanol : cholesterol ratio.
The percentage change of AHI was positively associated
with the respective changes of serum synthesis markers
(e.g., serum cholestenol : cholesterol ratio, Figure 2(a))
and inversely with the percentage change of serum
cholestanol : cholesterol ratio (Figure 2(b)). After adjustment
with gender and the percentage changes of BMI and HOMA-
IR, the associations between the percentage changes of
AHI and cholestanol : cholesterol ratio (𝑃 = 0.004) and of
the cholesterol synthesis markers cholestenol : cholesterol
(𝑃 = 0.021) remained significant. The positive associations
between the percentage changes of AHI and cholestenol,
desmosterol, and lathosterol ratios to cholestanol (𝑟 = 0.460–
0.519, 𝑃 = 0.001–0.003) remained significant after
adjustment with gender and the percentage changes of
BMI and HOMA-IR, too. However, the inverse associations
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Figure 1: The percentage changes in apnoea-hypopnoea index
(AHI), mean oxygen saturation (SaO2 ), and cholestenol and cho-
lestanol : cholesterol ratios (102xmmol/mol of cholesterol) in rela-
tion to changes in bodyweight: less than−10 kg,−10 to−5 kg, and−5
to 0 kg and more than 0 kg a𝑃 < 0.05 or less from weight reduction
of < −10 kg, b𝑃 < 0.05 or less from weight reduction of −5 to 0 kg.
between the percentage changes of SaO
2
and cholestenol
and desmosterol ratios to campesterol (𝑟 = −0.365–−0.375,
𝑃 = 0.024–0.026) did not remain significant after adjustment
with gender and the percentage changes of BMI and
HOMA-IR.
4. Discussion
The novel observations of the present study were that mild
OSA seems to be associated with cholesterol metabolism
independent of BMI and HOMA-IR. Secondly, one-year
weight reduction program resulted in changes in cholesterol
metabolism. Thirdly, after weight reduction the improve-
ment in OSA was associated with changes in cholesterol
metabolism independent of weight and HOMA-IR reduc-
tions.
Weight reduction achieved by intensive lifestyle coun-
selling with an initial VLCD program increased SaO
2
and
serum cholestanol : cholesterol ratio suggesting that choles-
terol absorption was increased. In addition, AHI and serum
cholestenol : cholesterol ratio was decreased suggesting that
cholesterol synthesis was downregulated. Similar findings
regarding cholesterol metabolism were reported in in type
2 diabetics [21, 22]. The present study also demonstrated
that all these changes sustained up to 1 year. The negative
interrelations of cholesterol synthesis and absorptionmarkers
at baseline and after one year (data not shown) suggest that
cholesterol homeostasis remained intact irrespective of the
intervention.
There is a definite need for further research to better
understand the links between OSA and lipid metabolism and
to improve the current guidelines of treatment. Thus far, the
interventional studies examining the effects ofOSA treatment
on lipid metabolism have exclusively been conducted with
continuous positive airway pressure (CPAP). However, the
evidence of the effects of CPAP treatment on dyslipidaemia is
limited. In one recent study, CPAP has been demonstrated to
reduce postprandial serum triglyceride and total cholesterol
concentrations [27] and in another, fasting serum choles-
terol, but not triglyceride concentrations [28]. The consen-
sus statement of International Diabetes Federation highly
recommends further research on OSA and metabolism in
general and particularly intervention studies with emphasis
on cardiovascular risk factors, also without using CPAP [29].
The statement concludes that management of OSA should
focus initially on weight reduction for the overweight and
obese. In general, weight reduction improves serum lipid
profile [30]. In the present study, weight reduction did not
change serum total and LDL cholesterol concentrations even
though it affected cholesterol metabolism.
In animal models, IH was suggested to induce dys-
lipidaemia by upregulating biosynthesis of VLDL in liver,
increasing lipolysis in adipocytes, and inhibiting lipoprotein
clearance [31–34]. Recently, in patients with OSA, hepatic
expression of stearoyl CoA desaturase, a key enzyme of lipid
biosynthesis, has been demonstrated to increase in direct
proportion to the severity of nocturnal IH [33]. In addi-
tion, overexpression was associated with marked increase in
plasma triglyceride and LDL cholesterol concentrations [33].
However, thus far there is no consistent evidence supporting
the relationship between OSA and dyslipidaemia in humans
[11–14].
Based on animal models, IH was suggested not to affect
cholesterol biosynthesis, because there was no effect on the
key genes involved in cholesterol biosynthesis [32]. However,
we found in the subjects with mild OSA that SaO
2
, one of the
key cardiorespiratory variables, was positively associatedwith
cholesterol absorption (serum campesterol : cholesterol ratio)
and inversely with cholesterol synthesis (serum desmos-
terol : cholesterol ratio) at baseline suggesting that the greater
SaO
2
, the greater the cholesterol absorption and the lower the
cholesterol synthesis. These associations were independent
from gender, BMI andHOMA-IR. In addition, although AHI
was not significantly associated with cholesterol absorption
markers, it tended to be associated positively with cholesterol
synthesis markers (cholestenol : cholesterol ratio, 𝑃 = 0.062).
In the whole study population, the greater the weight
reduction, the greater the reductions in AHI and serum
cholestenol : cholesterol ratio and the increases in SaO
2
and
serum cholestanol : cholesterol ratio. In addition, the per-
centage change of AHI was inversely associated with that of
cholesterol absorption marker (cholestanol) and positively
with the percentage change of cholesterol synthesis mark-
ers. This suggests that the more AHI was improved, the
more cholesterol absorption was increased and cholesterol
synthesis decreased. The associations between cholestanol
and of the cholesterol synthesis marker cholestenol and AHI
remained significant after adjustment with gender and the
percentage changes of BMI and HOMA-IR. On the contrary,
the relationships between the percentage changes of SaO
2
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Figure 2: The associations between the percentage changes in apnoea-hypopnoea index (AHI) and serum cholestenol ((a), 𝑟 = 0.589, 𝑃 <
0.001,𝑁 = 41) and cholestanol ratios to cholesterol (102 xmmol/mol of cholesterol) ((b), 𝑟 = −0.441, 𝑃 = 0.004,𝑁 = 41) in the control (I)
and intervention (∙) groups.
and cholesterol absorption and synthesis markers were to
opposite directions than with AHI, but the relationships did
not reached statistical significance.
Even mild OSA is associated with increased activation
of the inflammatory system and a risk for cardiovascular
morbidity, although the risk is more frequently associated
with more severe degrees of the disease [8–10]. The exact
underlying mechanisms explaining the association between
cardiovascular morbidity and OSA are not fully understood,
although a multifactorial aetiology is most likely [6]. It is
suggested that OSA may accelerate atherosclerosis affecting
the key risk factors of atherosclerosis. One of the proposed
potential mediators and accelerators of atherosclerosis in
OSA is postulated to be dysregulation of lipidmetabolism and
dyslipidaemia. Cholesterol absorption is low, and cholesterol
synthesis is high in obesity [17], insulin resistance [35],
and type 2 diabetes even without obesity [36]. In type 2
diabetes, weight reduction increased cholesterol absorption
and downregulated cholesterol synthesis simultaneously with
improved glucose balance [22]. Therefore, low absorption-
high synthesis of cholesterol might be proatherogenic in
insulin-resistant situations, possibly frequently present also
inOSA.This kind ofmetabolic profile of cholesterol of insulin
resistance is different from that observed in primary hyperc-
holesterolaemia, in which high absorption-low synthesis of
cholesterol is associated with unfavorable prognosis during
statin treatment in coronary subjects [37]. The present study
demonstrates that with weight reduction both OSA and the
possibly proatherogenic profile of cholesterol metabolism
can be improved. The intriguing question, however, is by
which mechanism the variables of OSA and cholesterol
metabolism are interrelated beyond obesity. Both at baseline
and after the intervention with improved tissue oxygenation
the associations between OSA and cholesterol metabolism
were similar: better oxygenation is associated with higher
absorption and lower synthesis of cholesterol independent of
BMI.
Our study population was homogenous consisting only
of overweight subjects with mild OSA. Therefore, the results
cannot be generalized to all OSA patients, and there exist
also some limitations in this study. The sample size per
group was relatively small, and it was smaller than in
the original study [20], because the subjects using lipid-
lowering medication had to be excluded. With larger study
population the results, which now tended to be significant,
might become significant. Furthermore, the sample size
of the present study is similar to those in other recent
interventional studies examining lipid metabolisms in OSA
patients. Because no stratification in terms of BMI was used
in the randomisation, the weight between the groups differed
at baseline.Therefore, we adjusted the results for the baseline
BMI. Furthermore, because serum insulin concentration and
cholestenol : cholesterol ratio were greater and HOMA-IR
tended to significantly greater in the intervention group
compared with controls at baseline, the baseline values were
taken into account as covariance in the analyses of those
variables. Regardless of some limitations, the present study is,
as far as we know, the first study to examine the associations
between OSA and cholesterol metabolism in humans and
with and without lifestyle intervention in a randomised
settings. Furthermore, this study demonstrated the evenmild
OSA seemed to be associated with abnormal cholesterol
metabolism.
CPAP is considered as a “gold standard” ofOSA treatment
[38]. However, the adherence of some patients to CPAP
treatment is unsatisfactory, particularly in the early stages of
the OSA. Based on the recent randomised studies and on the
fact that obesity is themost important risk factor forOSA and
most OSA patients are obese, weight reduction by lifestyle
changes (healthy eating habits, food behaviour therapy if
8 Cholesterol
needed and physical activity) should be the first line or at
least part of the treatment for all overweight OSA patients.
Besides improving OSA, weight reduction seems to improve
also other obesity-related disturbances of cardiometabolic
syndrome [20, 39].
In conclusion, weight reduction with intensive lifestyle
counselling with an initial VLCD program increased the
markers of cholesterol absorption and decreased those of
cholesterol synthesis in subjects with mild OSA. High SaO
2
seems to be associated with high cholesterol absorption
and low SaO
2
with upregulated cholesterol synthesis inde-
pendent of BMI, HOMA-IR, and gender. Improvement in
AHI was associated with increased cholesterol absorption
and decreased cholesterol synthesis independent of BMI and
HOMA-IR. However, further studies with greater number of
subjects are needed to confirm these results.
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